Acquisition advances Clario's Respiratory Solutions portfolio, combining Clario's deep scientific expertise with ArtiQ's innovative artificial intelligence capabilities

此次收购提升了Clario的呼吸解决方案组合，将Clario深厚的科学专业知识与ArtiQ创新的人工智能能力相结合

Clario's respiratory devices will integrate seamlessly with ArtiQ's AI models to provide instant feedback on test quality, delivering faster, more reliable data for sponsors and yielding a better patient experience.

Clario的呼吸设备将与ArtiQ的人工智能模型无缝集成，为测试质量提供即时反馈，为赞助商提供更快，更可靠的数据，并产生更好的患者体验。

The addition of ArtiQ, coupled with Clario's recent acquisition of Inofab Health, expands Clario's leadership position in supporting respiratory clinical trials and broadens the existing AI capability which encompasses over 50 proprietary AI/ML algorithms.

ArtiQ的加入，加上Clario最近收购Inofab Health，扩大了Clario在支持呼吸系统临床试验方面的领导地位，并扩大了现有的AI能力，其中包括50多种专有AI/ML算法。

ArtiQ CEO Marko Topalovic will join Clario and continue to lead ArtiQ while simultaneously leading AI at the company.

ArtiQ首席执行官马尔科·托帕洛维奇（MarkoTopalovic）将加入Clario，继续领导ArtiQ，同时领导公司的人工智能。

PHILADELPHIA, April 2, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the acquisition of the technology company ArtiQ. This acquisition expands the power of artificial intelligence (AI) in Clario's Respiratory Solutions portfolio and enhances the company's ability to further leverage and develop innovative uses of AI across its service lines..

费城，2024年4月2日/PRNewswire/--Clario是一家医疗保健研究和技术公司，为临床试验提供领先的端点技术解决方案，今天宣布收购技术公司ArtiQ。此次收购扩大了人工智能（AI）在Clario呼吸解决方案组合中的影响力，并增强了该公司在其服务线中进一步利用和开发人工智能创新用途的能力。

'We're thrilled to welcome ArtiQ into our organization,' said Chris Fikry, Chief Executive Officer at Clario. 'Since 2018, Clario has been a pioneer in applying artificial intelligence to improve the quality and efficiency of clinical trial execution. This move significantly advances AI within our respiratory portfolio.

Clario首席执行官克里斯·菲克里（ChrisFikry）说：“我们很高兴欢迎ArtiQ加入我们的组织。自2018年以来，Clario一直是应用人工智能提高临床试验执行质量和效率的先驱。这一举措显着提高了我们呼吸组合中的AI。

With ArtiQ's technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process for patients worldwide.'.

利用ArtiQ的技术，我们正在扩展我们的能力，以快速扩展AI以进行过度阅读，同时确保数据质量并简化全球患者的临床试验过程。”

In addition to continuing to lead ArtiQ, Marko Topalovic will step in to lead Clario's overall AI strategy across the organization. Of the acquisition, he said: 'Joining forces with Clario is a pivotal moment for ArtiQ. Our technology's integration into Clario's portfolio not only enhances the quality and efficiency of spirometry data analysis but also marks a sizable step toward minimizing the patient burden and improving trial outcomes.

除了继续领导ArtiQ之外，马尔科·托帕洛维奇（MarkoTopalovic）还将在整个组织内领导Clario的整体人工智能战略。关于此次收购，他说：“与Clario联手对ArtiQ来说是一个关键时刻。我们的技术整合到Clario的产品组合中，不仅提高了肺活量测定数据分析的质量和效率，而且标志着朝着最小化患者负担和改善试验结果迈出了相当大的一步。

With Clario, our technology can scale worldwide to all clinical trials and sponsors, and we now have the chance to foster a positive impact beyond the scope of respiratory care.'.

有了Clario，我们的技术可以在全球范围内扩展到所有临床试验和赞助商，我们现在有机会在呼吸护理范围之外产生积极影响。”

In addition to the ArtiQ acquisition, Clario acquired Inofab Health, the manufacturer of easy-to-use ultrasonic sensor spirometer devices, in November 2023. Bringing these acquisitions together with Clario's deep respiratory scientific capabilities will strengthen Clario's Respiratory Solutions portfolio, serve as a launchpad for advancing AI within clinical trials, and increase its reach into the broader healthcare market..

除收购ArtiQ外，Clario于2023年11月收购了易用超声波传感器肺活量计设备制造商Inofab Health。将这些收购与Clario的深呼吸科学能力结合起来，将加强Clario的呼吸解决方案组合，成为在临床试验中推进人工智能的启动平台，并扩大其在更广泛的医疗保健市场的影响力。

'We're committed to pioneering AI models that help rapidly deliver high-quality data in clinical trials,' said Jay Ferro, Clario's Chief Information, Technology and Product Officer. 'This acquisition reinforces that commitment and ensures we continue to make good on our mission to help our customers transform patient lives around the world.'.

Clario首席信息、技术和产品官杰伊·费罗（JayFerro）说，我们致力于开创人工智能模型，帮助在临床试验中快速提供高质量的数据此次收购强化了这一承诺，并确保我们继续履行使命，帮助客户改变世界各地的患者生活。”

To learn more about Clario's Respiratory Solutions portfolio and scientific expertise, please visit Clario.com.

要了解更多有关Clario呼吸解决方案组合和科学专业知识的信息，请访问Clario.com。

About Clario

关于Clario

Clario is a leading healthcare research and technology company that generates the highest quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints..

Clario是一家领先的医疗保健研究和技术公司，为我们的制药、生物技术和医疗设备合作伙伴提供最高质量的临床证据。我们提供综合证据生成解决方案，将eCOA，心脏安全，医学成像，精确运动和呼吸终点结合起来。

Clario's global team of science, technology, and operational experts have helped deliver over 26,000 trials and contributed to over 800 regulatory approvals in more than 100 countries. For more than 50 years, we have delivered deep scientific expertise and the broadest endpoint technologies to help transform lives around the world..

Clario的全球科学、技术和运营专家团队帮助完成了26000多项试验，并为100多个国家的800多项监管批准做出了贡献。50多年来，我们提供了丰富的科学专业知识和最广泛的端点技术，以帮助改变世界各地的生活。

For more information, go to Clario.com or follow us on LinkedIn.

有关更多信息，请访问Clario.com或在LinkedIn上关注我们。

About ArtiQ

关于ArtiQ

ArtiQ, a spin-off from the Belgian university KU Leuven, is a leading innovative software company dedicated to enhancing the diagnosis and monitoring of patients with respiratory conditions. Moreover, ArtiQ strives to streamline and optimize respiratory clinical trials for pharmaceutical companies. Through the development and provision of cutting-edge AI-first software, ArtiQ empowers traditional respiratory devices and processes..

ArtiQ是比利时鲁汶大学的附属公司，是一家领先的创新软件公司，致力于加强呼吸系统疾病患者的诊断和监测。此外，ArtiQ致力于为制药公司简化和优化呼吸系统临床试验。通过开发和提供先进的AI first软件，ArtiQ为传统的呼吸设备和流程提供了支持。

ArtiQ was launched in 2019 with the support of KU Leuven, University Hospitals Leuven, and the early investors Gemma Frisius Fund and KBC Focus Fund. Since then, together with researchers, clinicians, equipment manufacturers, and pharmaceutical companies, we are on a mission to make key improvements for patients with lung diseases. .

ArtiQ于2019年在鲁汶大学、鲁汶大学医院、早期投资者Gemma Frisius基金和KBC Focus基金的支持下成立。从那时起，我们与研究人员、临床医生、设备制造商和制药公司一道，致力于为肺部疾病患者做出关键改进。

More information can be found at www.artiq.eu or follow us on LinkedIn and Twitter.

更多信息可以在www.artiq.eu上找到，也可以在LinkedIn和Twitter上关注我们。